Xinlitai announced that JK06, an innovative drug developed by the company's holding subsidiary Salubris Bio, is currently undergoing phase I/II clinical trials in Europe. The domestic clinical trial application for JK06 injection submitted by the company was recently accepted by the State Drug Administration; if no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, the applicant can carry out clinical trials in accordance with the submitted plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.